Q4 2024 Charles River Laboratories International Inc Earnings Call Transcript
Key Points
- Charles River Laboratories International Inc (CRL) ended the year with a fourth-quarter performance that was slightly better than expected, with annual revenue and non-GAAP earnings per share exceeding guidance.
- The company has implemented restructuring initiatives expected to yield annualized savings of approximately $225 million by 2026, with over $175 million realized in 2025.
- Operating margin increased by 80 basis points year over year to 19.9% in the fourth quarter, driven by lower unallocated corporate costs and margin expansion in the Manufacturing segment.
- The Microbial Solutions business reported a strong year-end performance with solid growth across all three testing platforms.
- Charles River Laboratories International Inc (CRL) plans to repurchase approximately $350 million in stock over the next month or two, exceeding their initial goal of $100 million last year to offset annual dilution from equity awards.
- Charles River Laboratories International Inc (CRL) expects a revenue decline of 3.5% to 5.5% on an organic basis in 2025, with a reported revenue decline of 4.5% to 7% including a foreign exchange headwind.
- The company anticipates a modestly lower consolidated operating margin in 2025 due to the inability to fully offset the revenue decline, particularly in the DSA segment.
- DSA revenue is expected to decline at a mid- to high-single-digit rate on an organic basis in 2025, with both lower pricing and steady volume impacting the decline.
- The Manufacturing Solutions segment is expected to have essentially flat revenue in 2025 on an organic basis, with lower revenue from two commercial CDMO clients reducing consolidated revenue by approximately 1%.
- Free cash flow is expected to decrease to a range of $350 to $390 million in 2025, down from $501.6 million in 2024, driven by lower earnings and higher working capital needs.
Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories fourth quarter and full-year 2024 earnings conference call. This call is being recorded. (Operator Instructions)
I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations. Please go ahead, sir.
Good morning, and welcome to Charles River Laboratories fourth quarter and full-year 2024 earnings and 2025 guidance conference call and webcast. This morning, I am joined by Jim Foster, Chair, President, and Chief Executive Officer; and Flavia Pease, Executive Vice President and Chief Financial Officer. They will comment on our results for the fourth quarter of '24 as well as our financial guidance for 2025. Following the presentation, they will respond to questions.
There is a slide presentation associated with today's remarks, which is posted on the Investor Relations section of our website at ir.criver.com. A
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
